Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:


GlobeNewswire Inc | Nov 6, 2020 08:30AM EST

November 06, 2020

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

Cowen 2020 Next IO SummitFriday, November 13, 2020Fireside Chat time: 2:45 p.m. EST

Stifel 2020 Virtual Healthcare ConferenceWednesday, November 18, 2020Fireside Chat time: 4:40 p.m. EST

Evercore ISI 3rd Annual HealthCONxWednesday, December 2, 2020 Panel Discussion time: 10:30 a.m. ESTTitle: Finders Keepers: Identifying New Cancer Targets

Live audio webcasts of the Cowen and Stifel presentations can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. An archived replay of each webcast will be available on the company's website for 90 days following the live presentations.

About Atreca, Inc.Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atrecas platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

ContactsAtreca, Inc. Herb Cross Chief Financial Officerinfo@atreca.com

Investors: Alex Gray, 650-779-9251 agray@atreca.com

Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.comSource: Atreca, Inc.







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC